Feasibility of convalescent plasma therapy in severe COVID-19 patients with persistent SARS-CoV-2 viremia
© 2021 Wiley Periodicals LLC..
This study aims to assess the efficacy and safety of convalescent plasma therapy (CPT) in COVID-19 critically ill patients with protracted severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNAemia. A retrospective cohort study was conducted in intensive care unit (ICU). All patients with severe COVID-19 pneumonia for whom RNAemia remained positive more than 14 days after onset of the infection were included and given CPT. The primary objective was to evaluate SARS-CoV-2 RNAemia 7 days (D7) after CPT. A total of 14 patients were included and they received a median CPT volume of 828 ml (range: 817-960). CPT was administered in a median time of 14 days after ICU admission. At D7, 13/14 patients had negative SARS-CoV-2 blood PCR and one patient had negative blood PCR 11 days after CPT. At D7 and at D14, the clinical status was improved in 7/14 and 11/14 patients, respectively. The 28-day mortality rate was 14%. No CPT-related adverse effects had been reported. CPT is safe and may be efficient in patients with protracted RNAemia admitted in ICU for severe COVID-19 pneumonia. Randomized controlled trials are needed to confirm these results.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:93 |
|---|---|
| Enthalten in: |
Journal of medical virology - 93(2021), 9 vom: 04. Sept., Seite 5594-5598 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Camou, Fabrice [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Combination therapy |
|---|
| Anmerkungen: |
Date Completed 02.08.2021 Date Revised 16.07.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/jmv.27032 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM324953453 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM324953453 | ||
| 003 | DE-627 | ||
| 005 | 20231225191418.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/jmv.27032 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1083.xml |
| 035 | |a (DE-627)NLM324953453 | ||
| 035 | |a (NLM)33942327 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Camou, Fabrice |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Feasibility of convalescent plasma therapy in severe COVID-19 patients with persistent SARS-CoV-2 viremia |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 02.08.2021 | ||
| 500 | |a Date Revised 16.07.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2021 Wiley Periodicals LLC. | ||
| 520 | |a This study aims to assess the efficacy and safety of convalescent plasma therapy (CPT) in COVID-19 critically ill patients with protracted severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNAemia. A retrospective cohort study was conducted in intensive care unit (ICU). All patients with severe COVID-19 pneumonia for whom RNAemia remained positive more than 14 days after onset of the infection were included and given CPT. The primary objective was to evaluate SARS-CoV-2 RNAemia 7 days (D7) after CPT. A total of 14 patients were included and they received a median CPT volume of 828 ml (range: 817-960). CPT was administered in a median time of 14 days after ICU admission. At D7, 13/14 patients had negative SARS-CoV-2 blood PCR and one patient had negative blood PCR 11 days after CPT. At D7 and at D14, the clinical status was improved in 7/14 and 11/14 patients, respectively. The 28-day mortality rate was 14%. No CPT-related adverse effects had been reported. CPT is safe and may be efficient in patients with protracted RNAemia admitted in ICU for severe COVID-19 pneumonia. Randomized controlled trials are needed to confirm these results | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a SARS coronavirus | |
| 650 | 4 | |a combination therapy | |
| 650 | 4 | |a disease control | |
| 650 | 4 | |a generalized infection | |
| 650 | 4 | |a pathogenesis | |
| 650 | 4 | |a virus classification | |
| 650 | 7 | |a RNA, Viral |2 NLM | |
| 700 | 1 | |a Tinevez, Claire |e verfasserin |4 aut | |
| 700 | 1 | |a Beguet-Yachine, Mathilde |e verfasserin |4 aut | |
| 700 | 1 | |a Bellecave, Pantxika |e verfasserin |4 aut | |
| 700 | 1 | |a Ratiarison, Diana |e verfasserin |4 aut | |
| 700 | 1 | |a Tumiotto, Camille |e verfasserin |4 aut | |
| 700 | 1 | |a Lafarge, Xavier |e verfasserin |4 aut | |
| 700 | 1 | |a Guisset, Olivier |e verfasserin |4 aut | |
| 700 | 1 | |a Mourissoux, Gaëlle |e verfasserin |4 aut | |
| 700 | 1 | |a Lafon, Marie-Edith |e verfasserin |4 aut | |
| 700 | 1 | |a Bonnet, Fabrice |e verfasserin |4 aut | |
| 700 | 1 | |a Issa, Nahéma |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of medical virology |d 1990 |g 93(2021), 9 vom: 04. Sept., Seite 5594-5598 |w (DE-627)NLM000285676 |x 1096-9071 |7 nnns |
| 773 | 1 | 8 | |g volume:93 |g year:2021 |g number:9 |g day:04 |g month:09 |g pages:5594-5598 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/jmv.27032 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 93 |j 2021 |e 9 |b 04 |c 09 |h 5594-5598 | ||